PMID- 22710387
OWN - NLM
STAT- MEDLINE
DCOM- 20130423
LR  - 20211021
IS  - 1531-7013 (Electronic)
IS  - 1087-2418 (Print)
IS  - 1087-2418 (Linking)
VI  - 17
IP  - 4
DP  - 2012 Aug
TI  - HLA class I antibody-mediated endothelial and smooth muscle cell activation.
PG  - 446-51
LID - 10.1097/MOT.0b013e328355f1c2 [doi]
AB  - PURPOSE OF REVIEW: Advances in immunosuppression and patient management have 
      successfully improved 1-year transplant outcome. Unfortunately, antibody-mediated 
      rejection is a major barrier to long-term graft survival. This study summarizes 
      the effects of antibodies on endothelial cell and smooth muscle cell (SMC) 
      migration, proliferation and leukocyte recruitment, emphasizing the intracellular 
      signaling pathways that orchestrate these distinct functional outcomes. RECENT 
      FINDINGS: Several studies have provided further insight into the effects of human 
      leukocyte antigen (HLA) class I antibodies on vascular cells. We found that HLA I 
      molecules partner with integrin beta4 to transduce proliferative signaling, and 
      identified proteins that associate with the cytoskeleton after HLA class I 
      crosslinking. Natural killer cells have been strongly implicated in a murine 
      model of donor-specific major histocompatibility complex I antibody-triggered 
      neointimal thickening. A recently developed human arterial graft model revealed 
      the role of matrix metalloproteinases in SMC mitogenesis by HLA class I 
      antibodies. Using a donor transgenic for HLA-A2, Fukami et al. investigated the 
      mechanisms of accommodation induced by low titers of HLA class I antibodies. 
      SUMMARY: Ligation of HLA class I molecules with antibodies leads to the 
      activation of intracellular signals in endothelial cells and SMCs, which in turn 
      promote actin cytoskeletal remodeling, survival, proliferation, and recruitment 
      of leukocytes.
FAU - Zhang, Xiaohai
AU  - Zhang X
AD  - Department of Pathology, UCLA Immunogenetics Center, David Geffen School of 
      Medicine, University of California, Los Angeles, California 90095, USA.
FAU - Valenzuela, Nicole M
AU  - Valenzuela NM
FAU - Reed, Elaine F
AU  - Reed EF
LA  - eng
GR  - R01 HL090995/HL/NHLBI NIH HHS/United States
GR  - R01 HL 090995/HL/NHLBI NIH HHS/United States
GR  - R01 AI 042819/AI/NIAID NIH HHS/United States
GR  - R01 AI042819/AI/NIAID NIH HHS/United States
GR  - U01AI077821/AI/NIAID NIH HHS/United States
GR  - 5T32 HL69766-10/HL/NHLBI NIH HHS/United States
GR  - U01 AI077821/AI/NIAID NIH HHS/United States
GR  - T32 HL069766/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Curr Opin Organ Transplant
JT  - Current opinion in organ transplantation
JID - 9717388
RN  - 0 (Actins)
RN  - 0 (Antibodies)
RN  - 0 (HLA Antigens)
RN  - 0 (Integrin beta4)
SB  - IM
MH  - Actins/immunology
MH  - Animals
MH  - Antibodies/immunology
MH  - Cell Proliferation
MH  - Cell Survival
MH  - Chemotaxis, Leukocyte
MH  - Cytoskeleton/immunology
MH  - Endothelial Cells/*immunology
MH  - Endothelium, Vascular/cytology/*immunology
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Integrin beta4/immunology
MH  - Myocytes, Smooth Muscle/*immunology
MH  - Signal Transduction
PMC - PMC3880156
MID - NIHMS540647
COIS- Conflicts of interest The authors have no conflicts of interest to disclose.
EDAT- 2012/06/20 06:00
MHDA- 2013/04/24 06:00
PMCR- 2014/01/03
CRDT- 2012/06/20 06:00
PHST- 2012/06/20 06:00 [entrez]
PHST- 2012/06/20 06:00 [pubmed]
PHST- 2013/04/24 06:00 [medline]
PHST- 2014/01/03 00:00 [pmc-release]
AID - 10.1097/MOT.0b013e328355f1c2 [doi]
PST - ppublish
SO  - Curr Opin Organ Transplant. 2012 Aug;17(4):446-51. doi: 
      10.1097/MOT.0b013e328355f1c2.